Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) CEO Christopher Gibson sold 36,825 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $9.49, for a total value of $349,469.25. Following the transaction, the chief executive officer now owns 541,829 shares of the company’s stock, valued at $5,141,957.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Christopher Gibson also recently made the following trade(s):
- On Thursday, July 7th, Christopher Gibson sold 37,114 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.05, for a total value of $335,881.70.
- On Thursday, June 2nd, Christopher Gibson sold 39,690 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.09, for a total value of $241,712.10.
Recursion Pharmaceuticals Price Performance
Shares of NASDAQ:RXRX opened at $9.91 on Friday. The business’s 50 day moving average price is $7.92 and its 200-day moving average price is $8.10. The firm has a market capitalization of $1.69 billion, a PE ratio of -7.43 and a beta of -0.48. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.92 and a 1 year high of $31.43.
Institutional Investors Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System purchased a new stake in Recursion Pharmaceuticals in the second quarter valued at $304,000. Nisa Investment Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 7,064.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 77,380 shares of the company’s stock valued at $630,000 after buying an additional 76,300 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $310,000. Centaurus Financial Inc. acquired a new position in Recursion Pharmaceuticals during the 2nd quarter worth $82,000. Finally, US Bancorp DE acquired a new position in Recursion Pharmaceuticals during the 2nd quarter worth $132,000. Hedge funds and other institutional investors own 55.25% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have commented on RXRX. The Goldman Sachs Group dropped their price objective on Recursion Pharmaceuticals from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th. Bank of America lowered Recursion Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a report on Monday, April 18th.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.